Hongwei Xu

Researcher

UAMS

Also affiliated: Winthrop Rockefeller Foundation (2022–2025); Arkansas Children's Nutrition Center (2025)

Faculty Researcher

2 h-index 13 pubs 31 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Hongwei Xu's research focuses on the molecular mechanisms underlying various diseases, with a particular emphasis on cancer and immune system function. His work has investigated the role of extracellular vesicles and microRNAs in disease progression, as well as the development of novel therapeutic strategies for conditions like multiple myeloma and hepatocellular carcinoma. Xu has published on the modulation of protein deubiquitination in B cell malignancies and the potential of bispecific CAR-T cells for controlling myeloma growth. His research also extends to diagnostic applications, such as the development of ultrasensitive detection systems for microRNAs in esophageal cancer serum and the evaluation of serum pepsinogen levels for gastric cancer screening. Xu collaborates with researchers at the University of Arkansas for Medical Sciences, including David E. Mery, Visanu Wanchai, Fenghuang Zhan, and Fumou Sun, with whom he has co-authored multiple publications.

Metrics

h-index: 2
Publications: 13
Citations: 31

Selected Publications

Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

Blood DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)

Cancer Research DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

Cancers 1 citation DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

Blood DOI OpenAlex
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression (2024)

Blood DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

Blood DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

Blood 1 citation DOI OpenAlex
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)

Blood DOI OpenAlex
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)

Blood DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

Blood Cancer Journal 35 citations DOI OpenAlex
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)

Research Square 1 citation DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

Nature Communications 46 citations DOI OpenAlex